Published mark
Aura Biosciences, Inc.
NASDAQ: AURA. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:231a016a-a5d3-483c-9443-13d5b2679516
- SEC CIK
- 0001501796
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 16, 2026
- Newest evidence
- Apr 20, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Elisabet de los Pinos, Ph.D.Since Apr 20, 2026
- Chair
- Not published
- Independent
- 5 / 66 directors published
- Published claims
- 242 distinct sources
- Evidence records
- 60 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 6 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
EXECUTIVE APPOINTED
Anthony Gibney executive of Aura Biosciences, Inc., effective 2026-04-20.
EffectiveEffective Apr 20, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Financial and Business Officer | Anthony Gibney | Apr 2026 | current | Source reportedE3 |
| President and Chief Executive Officer | Elisabet de los Pinos, Ph.D. | Apr 2026 | current | Source reportedE4 |
| Named Executive Officer | J. Jill Hopkins, M.D. | Apr 2026 | current | Source reportedE5 |
Board of directors
Evidence6 directors published. 5 of 6 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Antony Mattessich | Independent | 2021 | AuditAudit; Nominating and Governance · ChairNominating and Governance, chair | Source reportedE2 |
| David Johnson | Independent | 2021 | Nominating and Governance | Source reportedE2 |
| Elisabet de los Pinos, Ph.D. | Not independent | 2009 | None published | Source reportedE2 |
| Giovanni Mariggi, Ph.D. | Independent | 2019 | None published | Source reportedE2 |
| Sapna Srivastava | Independent | 2021 | Audit, chairAudit · Chair | Source reportedE2 |
| Teresa Marie Bitetti | Independent | 2025 | Compensation | Source reportedE2 |
| Karan Takhar | Independent | Not published | CompensationCompensation; Nominating and GovernanceNominating and Governance | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Sapna Srivastava | Sapna Srivastava, Antony Mattessich | Not described in the published record |
| Audit · Chair | Not published | Sapna Srivastava | Not described in the published record |
| Audit; Nominating and Governance · Chair | Not published | Antony Mattessich | Not described in the published record |
| Compensation | Not published | Karan Takhar, Teresa Marie Bitetti | Not described in the published record |
| Compensation; Nominating and Governance | Not published | Karan Takhar | Not described in the published record |
| Nominating and Governance | Antony Mattessich | Antony Mattessich, David Johnson, Karan Takhar | Not described in the published record |
Committee RecordAudit: Chair Sapna Srivastava; Members Sapna Srivastava (Chair); Antony Mattessich
Committee AppointmentSapna Srivastava: chair, Audit
Committee AppointmentAntony Mattessich: member, Audit
Committee RecordCompensation: Chair not stated; Members Karan Takhar; Teresa Marie Bitetti
Committee AppointmentKaran Takhar: member, Compensation
Committee AppointmentTeresa Marie Bitetti: member, Compensation
Committee RecordNominating and Governance: Chair Antony Mattessich; Members Antony Mattessich (Chair); David Johnson; Karan Takhar
Committee AppointmentAntony Mattessich: chair, Nominating and Governance
Committee AppointmentDavid Johnson: member, Nominating and Governance
Committee AppointmentKaran Takhar: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerElisabet de los Pinos, Ph.D., President and Chief Executive Officer, from Apr 20, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingAURA (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 16, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameAura Biosciences, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Anthony GibneyChief Financial and Business Officercompany:231a016a-a5d3-483c-9443-13d5b2679516:leadership_role:12
- Elisabet de los Pinos, Ph.D.President and Chief Executive Officercompany:231a016a-a5d3-483c-9443-13d5b2679516:leadership_role:13
- J. Jill Hopkins, M.D.Named Executive Officercompany:231a016a-a5d3-483c-9443-13d5b2679516:leadership_role:14
- Antony MattessichDirectorcompany:231a016a-a5d3-483c-9443-13d5b2679516:leadership_role:5
- David JohnsonDirectorcompany:231a016a-a5d3-483c-9443-13d5b2679516:leadership_role:6
- Elisabet de los Pinos, Ph.D.Directorcompany:231a016a-a5d3-483c-9443-13d5b2679516:leadership_role:7
- Giovanni Mariggi, Ph.D.Directorcompany:231a016a-a5d3-483c-9443-13d5b2679516:leadership_role:8
- Sapna SrivastavaDirectorcompany:231a016a-a5d3-483c-9443-13d5b2679516:leadership_role:10
- Teresa Marie BitettiDirectorcompany:231a016a-a5d3-483c-9443-13d5b2679516:leadership_role:11
- Karan TakharDirectorcompany:231a016a-a5d3-483c-9443-13d5b2679516:leadership_role:9
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 6 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 20, 2026. Retrieved Apr 24, 2026. Cited by 7 Claims.
- E3sec filing. Published Apr 20, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E4sec filing. Published Apr 20, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 20, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E6board_seats. board seats. Cited by 10 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 16, 2026- Anthony Gibney executive of Aura Biosciences, Inc., effective 2026-04-20.
- Elisabet de los Pinos, Ph.D. executive of Aura Biosciences, Inc., effective 2026-04-20.
- J. Jill Hopkins, M.D. executive of Aura Biosciences, Inc., effective 2026-04-20.
- Teresa Marie Bitetti seat on Aura Biosciences, Inc., effective 2025-01-01.
- Antony Mattessich seat on Aura Biosciences, Inc., effective 2021-01-01.
- David Johnson seat on Aura Biosciences, Inc., effective 2021-01-01.
- Sapna Srivastava seat on Aura Biosciences, Inc., effective 2021-01-01.
- Audit · Chair committee of Aura Biosciences, Inc., effective 2021-01-01.
- Sapna Srivastava member of Audit · Chair, effective 2021-01-01.
- Audit; Nominating and Governance · Chair committee of Aura Biosciences, Inc., effective 2021-01-01.
- Antony Mattessich member of Audit; Nominating and Governance · Chair, effective 2021-01-01.
- David Johnson member of Nominating and Governance, effective 2021-01-01.
- Giovanni Mariggi, Ph.D. seat on Aura Biosciences, Inc., effective 2019-01-01.
- Elisabet de los Pinos, Ph.D. seat on Aura Biosciences, Inc., effective 2009-01-01.